Part 2: Three Dividend Stocks You Must Buy – GlaxoSmithKline plc (GSK), The Coca-Cola Company (KO)

Despite the uncertainties of Fiscal Cliff, dividend stocks have emerged as a rock solid investment. Given how tough it is to get income from other alternatives, dividend stocks are likely to remain an essential part of the portfolio of those income hungry investors who live off their investments. With alternative income producing options offering low interest rates and banks offering meager returns on saving accounts, investors have had a little choice other than scouring for dividend paying stocks. In continuation to my last post, I explored the investing landscape a bit more to identify three more dividend stocks which can be a great addition to any investor’s portfolio. Let’s discuss each of these stocks in detail.

Companies 5 year average yield Forward annual yield Payout Ratio
GlaxoSmithKline plc (NYSE:GSK) 4.80% 5.10% 78.0%
Gannett Co., Inc. (NYSE:GCI) 5.70% 4.30% 37.0%
The Coca-Cola Company (NYSE:KO) 2.80% 2.70% 52.0%

Source: Yahoo Finance

GlaxoSmithKline plc (ADR) (NYSE:GSK)

GlaxoSmithKline

The company’s stock price has again gained momentum after hitting a low of ~$41 in November post its third quarter results. The overall performance of the company was impacted by a weak market in Europe. In 2012, the company witnessed price cuts in Europe that squeezed its gross margins. However, I expect this burden to have less effect in the fourth quarter results as the company has now stabilized its operations in Europe by cutting its costs. It included major headcount reductions in EU management, divesting its EU headquarters operations, and combining the EU and emerging markets management teams. Moreover, Glaxo has concentrated its focus on Europe in its R&D mix and is emphasizing more on Japan, China, and Brazil. These corrective measures should help Glaxo in posting steady returns in 2013.

Another positive for Glaxo is its well-placed position in therapeutic cancer vaccines. The company is running trials for MAGE-A3 for metastatic melanoma and non-small cell lung cancer. Looking at the company’s strong record of very less number of errors in clinical trials, I feel this is a good chance for Glaxo to make a breakthrough. The phase II trials have already shown good results and the same statistical significance is expected from phase III results, to be released by mid of 2013. I expect ~10% upside to the company’s value on the release of positive data. The company could be a strong beneficiary in this area, as this a high risk-reward opportunity.

Gannett

Gannett is a consistent dividend payer in Buffett’s portfolio with an average of ~5.7% dividend yield in the last five years. Also the shareholders have all the reasons to celebrate with the company’s stock price mounting upwards with a solid return of ~40% in the last six months. It is currently trading at ~$20, which is its highest level in the last two years. Gannett has been successful in adapting to the changing needs of media by adding new revenue generating channels. A further upside is expected in its stock price considering its subscription revenue growth in 2013. Additionally, the company’s content subscription model has been launched in 78 markets and is expecting the revenue to increase by ~25%. This in turn would generate ~$100 million of operating profit in 2013. I further expect the Gannett’s digital subscribers to grow by 5-7x in 2013.

Apart from this, the company’s cash flow is at ~14% of its sales which is highest among its peers. And, I expect it to generate ~700 million of FCF in 2013. The funds could be used in buying out assets of CareerBuilder which the Tribune Co has announced after coming out of bankruptcy. Gannett already has ~53% stake in this company and it would be the first choice for further investment. I feel this move would help the company to add another stream of revenue along with reducing its dependence on newspapers.

The Coca-Cola Company

The Coca-Cola Company has the highest share in Warren’s Portfolio with a ~20% holding. With lots of ups and downs, the company’s stock has given a return of just ~4% in 2012. This was majorly due to a tough macro environment because of the rising health issues for the beverages companies. Coca-Cola generates ~45% of its sales from North America; therefore it is more likely to get affected by the disappointing volume trends of this region. As per the recent data about the US CSDs (carbonated soft drinks), the overall sales decreased by ~1.1% for the quad week ending 22 Dec ’12. And, Coca-Cola brands witnessed a volume decline of ~2.9% for the same period which offsets the benefit of the price increase of ~1.6%. This led to an overall decline of 50 bps in the company’s market share. I feel the main reason behind this decline is the increasing health and wellness awareness among the customers. This remains a major headwind for such companies which are facing intensified pressure from various health groups thus affecting their sales volumes.

Considering this difficult environment in North America, Coca-Cola is venturing into other markets aiming at boosting its market presence. The company has announced its decision to invest ~$1.3 billion till 2016 to enhance its share in the South American region. As part of this initiative, Coca-Cola has joined hands with its regional bottler Coca-Cola Andina and has invested ~$200 million in a bottling plant in Renca. I feel this to be a good move by the company as Chile has the highest per capita consumption of CSD in South America. And, with this focus, I expect its market share to further enhance pushing out its competitors. This would also benefit the company during the major events such as FIFA world cups and Olympics in this region scheduled in the next four years.

Conclusion

To sum it up, I feel both the companies Glaxo and Gannett offer a good investing opportunity considering their history in dividend and also the future growth fundamentals. On the other hand, Coca-Cola is adapting itself towards a tough macro environment and slower demand in the US, which I feel is likely to continue in the future. However, its improved focus on the emerging nations could benefit the company in the long run.

The article Part 2: Three Dividend Stocks You Must Buy originally appeared on Fool.com and is written by Madhu Dube.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

The 10 Biggest Outlet Malls in USA

The 5 Most Popular Rap Songs of All Time

The 10 Countries that Eat the Most Meat

The10 Most Expensive Countries to Fly To

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!